Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

1articles mentioning institutions

1institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: NCT06843239 ×

NCT06843239

This institution is selected. Its supporting articles are shown below.

NCT068432391

Articles mentioning NCT06843239

1 articles · page 1 of 1

P.267 Tibusure: a phase 2, global, randomized, double-blind, placebo-controlled study with open-label extension to evaluate the efficacy, safety, and tolerability of tibulizumab in systemic sclerosis

jsrd · abstract · 2026-06-05 · 1 matching annotations

84.9%

NCT06843239 Tibulizumab Health Assessment Questionnaire Systemic sclerosis (SSc)Sjögren’s syndrome

…er 24-weeks, followed by a 28-week open-label extension (OLE) ( NCT06843239).Approximately 80 adults aged 18–75 years with dcSSc less than/…